Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report  

作　　者：Hai-Ping Liang Xing-Chun Luo Ya-Li Zhang Bei Liu 

机构地区：[1]The First Clinical Medical College,Lanzhou University,Lanzhou 730000,Gansu Province,China [2]Department of Hematology,The First Affiliated Hospital,Lanzhou University,Lanzhou 730000,Gansu Province,China

出　　处：《World Journal of Clinical Cases》2022年第11期3601-3608,共8页世界临床病例杂志

摘　　要：BACKGROUND Del(5q)is the most common molecular event in myelodysplastic syndrome(MDS),accounting for 10%-15%of cases.Inv(3)is an adverse cytogenetic abnormality observed in less than 1%of MDS patients.Few studies have reported the coexistence of del(5q)and inv(3)in MDS.Therefore,the pathological mechanism,treatment strategy and prognosis of this subtype need to be elucidated.CASE SUMMARY A 66-year-old woman was admitted to the hospital due to chest tightness and shortness of breath.Combining clinical assessments with laboratory examinations,the patient was diagnosed with MDS containing both del(5q)and inv(3).Considering the deletion of chromosome 5q,we first treated the patient with lenalidomide.When drug resistance arose,we tried azacitidine,and the patient had a short remission.Finally,the patient refused treatment with haematopoietic stem cell transplantation and died of severe infection four months later.CONCLUSION MDS patients with del(5)and inv(3)have a poor prognosis.Azacitidine may achieve short-term remission for such patients.

关 键 词：Myelodysplastic syndrome Del(5q) Inv(3) LENALIDOMIDE AZACITIDINE Case report 

分 类 号：R551.3[医药卫生—血液循环系统疾病]